As of March 2025, the U.S. stock market is experiencing increased volatility, with significant corrections in major indices like the Nasdaq Composite due to ongoing trade policy uncertainties and concerns over high valuations. Amid these turbulent conditions, growth companies with high insider ownership often attract attention because their stakes suggest a strong alignment between management and shareholder interests, potentially offering resilience in challenging economic climates.
Top 10 Growth Companies With High Insider Ownership In The United States
Overview: AAON, Inc. is involved in the engineering, manufacturing, marketing, and selling of air conditioning and heating equipment across the United States and Canada, with a market cap of approximately $6.69 billion.
Operations: The company's revenue segments include Basx at $198.72 million, AAON Oklahoma at $865.05 million, and AAON Coil Products at $182.24 million.
Insider Ownership: 17.4%
Return On Equity Forecast: 24% (2027 estimate)
AAON, Inc. is poised for significant growth with earnings expected to increase by 21.4% annually, outpacing the US market average. Despite recent insider selling, the company maintains robust insider ownership, indicating confidence in its long-term prospects. AAON's revenue is forecasted to grow at 14.4% per year and its Return on Equity is projected to reach a high of 24%. The appointment of Matt Tobolski as CEO signals strategic leadership continuity and focus on expanding data center cooling capabilities for sustained growth.
Overview: ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines to enhance the natural immune system against cancers and infectious diseases, with a market cap of approximately $2.61 billion.
Operations: The company generates revenue from its biotechnology segment, totaling $14.75 million.
Insider Ownership: 34.6%
Return On Equity Forecast: N/A (2027 estimate)
ImmunityBio's recent developments highlight its potential as a growth company with substantial insider ownership. The company's revenue surged to US$14.75 million in 2024, while net losses narrowed significantly. ImmunityBio's ANKTIVA received FDA approval and an RMAT designation, enhancing its prospects in cancer treatment. Despite financial challenges, including negative equity and a limited cash runway, the company's innovative pipeline and strategic collaborations position it for future growth amid high market expectations for revenue expansion.
Overview: Cadre Holdings, Inc. manufactures and distributes safety equipment designed for protection in hazardous situations both in the United States and internationally, with a market cap of approximately $1.33 billion.
Operations: The company's revenue is primarily derived from its Product segment, which accounts for $449.48 million, and its Distribution segment, contributing $99.39 million.
Insider Ownership: 33.4%
Return On Equity Forecast: N/A (2027 estimate)
Cadre Holdings is positioned for growth with substantial insider ownership, despite recent significant insider selling. The company's revenue is forecast to grow at 11% annually, surpassing the US market average. Earnings are projected to increase by a notable 30.1% per year, driven by strategic acquisitions and a robust financial position bolstered by US$458 million in available capital. Recent board changes and executive expertise further support Cadre's growth trajectory amid ongoing expansion efforts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
